October 28, 2020 /

Catabasis Phase 3 PolarisDMD Trial Results (October 27, 2020)

On October 26, 2020 Catabasis announced that the Phase 3 PolarisDMD trial of edasalonexent in Duchenne muscular dystrophy did not meet its primary or secondary endpoints. Catabasis joined PPMD for a webinar on October 27, 2020 to discuss the trial and results in more detail, as well as the company’s plans for the edasalonexent program going forward.

Posted on October 28, 2020

Join Our Mailing List